The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

被引：809

作者：

Kotschy, Andras ^{[1
]}

Szlavik, Zoltan ^{[1
]}

Murray, James ^{[2
]}

Davidson, James ^{[2
]}

Maragno, Ana Leticia ^{[3
]}

Le Toumelin-Braizat, Gaetane ^{[3
]}

Chanrion, Maia ^{[3
]}

Kelly, Gemma L. ^{[4
,5
]}

Gong, Jia-Nan ^{[4
,5
]}

Moujalled, Donia M. ^{[6
]}

Bruno, Alain ^{[3
]}

Sekei, Marton C. ^{[1
]}

Paczal, Attila ^{[1
]}

Szabo, Zoltan B. ^{[1
]}

Sipos, Szabolcs ^{[1
]}

Radics, Gabor ^{[1
]}

Proszenyak, Agnes ^{[1
]}

Balint, Balazs ^{[1
]}

Ondi, Levente ^{[1
]}

Blasko, Gabor ^{[1
]}

Robertson, Alan ^{[2
]}

Surgenor, Allan ^{[2
]}

Dokurno, Pawel ^{[2
]}

Chen, Ijen ^{[2
]}

Matassova, Natalia ^{[2
]}

Smith, Julia ^{[2
]}

Pedder, Christopher ^{[2
]}

Graham, Christopher ^{[2
]}

Studeny, Aurelie ^{[3
]}

Lysiak-Auvity, Gaelle ^{[3
]}

Girard, Anne-Marie ^{[3
]}

Grave, Fabienne ^{[3
]}

Segal, David ^{[4
,5
]}

Riffkin, Chris D. ^{[4
,5
]}

Pomilio, Giovanna ^{[6
]}

Galbraith, Laura C. A. ^{[4
,5
]}

Aubrey, Brandon J. ^{[4
,5
,7
]}

Brennan, Margs S. ^{[4
,5
]}

Herold, Marco J. ^{[4
,5
]}

Chang, Catherine ^{[4
,5
]}

Guasconi, Ghislaine ^{[3
]}

Auquil, Nicolas C. ^{[3
]}

Melchiore, Fabien ^{[8
]}

Guigal-Stephan, Nolwen ^{[8
]}

Lockhart, Brian ^{[8
]}

Colland, Frederic ^{[3
]}

Hickman, John A. ^{[3
]}

Roberts, Andrew W. ^{[4
,5
,9
]}

Huang, David C. S. ^{[4
,5
]}

Wei, Andrew H. ^{[6
,10
]}

机构：

[1] Servier Res Inst Med Chem, H-1031 Budapest, Hungary

[2] Vernalis R&D Ltd, Cambridge CB21 6GB, England

[3] Inst Rech Servier Oncol, R&D Unit, F-78290 Croissy Sur Seine, France

[4] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3052, Australia

[5] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia

[6] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia

[7] Royal Melbourne Hosp, Victorian Comprehens Canc Ctr, Dept Clin Haematol & Bone Marrow Transplantat, Melbourne, Vic 3050, Australia

[8] Inst Rech Servier, Biomarker Res Div, F-78290 Croissy Sur Seine, France

[9] Univ Melbourne, Fac Med, Melbourne, Vic 3010, Australia

[10] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic 3004, Australia

[11] Univ Melbourne, Dept Pharmacol & Pharmaceut, Melbourne, Vic 3010, Australia

来源：

NATURE | 2016年 / 538卷 / 7626期

基金：

英国医学研究理事会;

关键词：

ANTI-APOPTOTIC MCL-1; BCL-XL; MULTIPLE-MYELOMA; HIGH-AFFINITY; TUMOR-CELLS; SURVIVAL; PROTEIN; COMBINATION; DEPENDENCY; NAVITOCLAX;

D O I：

10.1038/nature19830

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

引用

页码：477 / +

页数：20

共 51 条

[1] THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE [J].

ADAMS, JM ;

HARRIS, AW ;

PINKERT, CA ;

CORCORAN, LM ;

ALEXANDER, WS ;

CORY, S ;

PALMITER, RD ;

BRINSTER, RL .

NATURE, 1985, 318 (6046) :533-538

[2] Mcl-1 is a potential therapeutic target in multiple types of cancer [J].

Akgul, C. .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (08) :1326-1336

[3] An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo [J].

Aubrey, Brandon J. ;

Kelly, Gemma L. ;

Kueh, Andrew J. ;

Brennan, Margs S. ;

O'Connor, Liam ;

Milla, Liz ;

Wilcox, Stephen ;

Tai, Lin ;

Strasser, Andreas ;

Herold, Marco J. .

CELL REPORTS, 2015, 10 (08) :1422-1432

[4] The landscape of somatic copy-number alteration across human cancers [J].

Beroukhim, Rameen ;

Mermel, Craig H. ;

Porter, Dale ;

Wei, Guo ;

Raychaudhuri, Soumya ;

Donovan, Jerry ;

Barretina, Jordi ;

Boehm, Jesse S. ;

Dobson, Jennifer ;

Urashima, Mitsuyoshi ;

Mc Henry, Kevin T. ;

Pinchback, Reid M. ;

Ligon, Azra H. ;

Cho, Yoon-Jae ;

Haery, Leila ;

Greulich, Heidi ;

Reich, Michael ;

Winckler, Wendy ;

Lawrence, Michael S. ;

Weir, Barbara A. ;

Tanaka, Kumiko E. ;

Chiang, Derek Y. ;

Bass, Adam J. ;

Loo, Alice ;

Hoffman, Carter ;

Prensner, John ;

Liefeld, Ted ;

Gao, Qing ;

Yecies, Derek ;

Signoretti, Sabina ;

Maher, Elizabeth ;

Kaye, Frederic J. ;

Sasaki, Hidefumi ;

Tepper, Joel E. ;

Fletcher, Jonathan A. ;

Tabernero, Josep ;

Baselga, Jose ;

Tsao, Ming-Sound ;

Demichelis, Francesca ;

Rubin, Mark A. ;

Janne, Pasi A. ;

Daly, Mark J. ;

Nucera, Carmelo ;

Levine, Ross L. ;

Ebert, Benjamin L. ;

Gabriel, Stacey ;

Rustgi, Anil K. ;

Antonescu, Cristina R. ;

Ladanyi, Marc ;

Letai, Anthony .

NATURE, 2010, 463 (7283) :899-905

[5] Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity [J].

Bruncko, Milan ;

Wang, Le ;

Sheppard, George S. ;

Phillips, Darren C. ;

Tahir, Stephen K. ;

Xue, John ;

Erickson, Scott ;

Fidanze, Steve ;

Fry, Elizabeth ;

Hasvold, Lisa ;

Jenkins, Gary J. ;

Jin, Sha ;

Judge, Russell A. ;

Kovar, Peter J. ;

Madar, David ;

Nimmer, Paul ;

Park, Chang ;

Petros, Andrew M. ;

Rosenberg, Saul H. ;

Smith, Morey L. ;

Song, Xiaohong ;

Sun, Chaohong ;

Tao, Zhi-Fu ;

Wang, Xilu ;

Xiao, Yu ;

Zhang, Haichao ;

Tse, Chris ;

Leverson, Joel D. ;

Elmore, Steven W. ;

Souers, Andrew J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) :2180-2194

[6] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function [J].

Chen, L ;

Willis, SN ;

Wei, A ;

Smith, BJ ;

Fletcher, JI ;

Hinds, MG ;

Colman, PM ;

Day, CL ;

Adams, JM ;

Huang, DCS .

MOLECULAR CELL, 2005, 17 (03) :393-403

[7] Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models [J].

Corcoran, Ryan B. ;

Cheng, Katherine A. ;

Hata, Aaron N. ;

Faber, Anthony C. ;

Ebi, Hiromichi ;

Coffee, Erin M. ;

Greninger, Patricia ;

Brown, Ronald D. ;

Godfrey, Jason T. ;

Cohoon, Travis J. ;

Song, Youngchul ;

Lifshits, Eugene ;

Hung, Kenneth E. ;

Shioda, Toshi ;

Dias-Santagata, Dora ;

Singh, Anurag ;

Settleman, Jeffrey ;

Benes, Cyril H. ;

Mino-Kenudson, Mari ;

Wong, Kwok-Kin ;

Engelman, Jeffrey A. .

CANCER CELL, 2013, 23 (01) :121-128

[8] Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic [J].

Cragg, Mark S. ;

Jansen, Elisa S. ;

Cook, Michele ;

Harris, Claire ;

Strasser, Andreas ;

Scott, Clare L. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (11) :3651-3659

[9] Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics [J].

Cragg, Mark S. ;

Harris, Claire ;

Strasser, Andreas ;

Scott, Clare L. .

NATURE REVIEWS CANCER, 2009, 9 (05) :321-326

[10] Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy [J].

Czabotar, Peter E. ;

Lessene, Guillaume ;

Strasser, Andreas ;

Adams, Jerry M. .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (01) :49-63

← 1 2 3 4 5 6 →